Clinical Research

South Shore Neurologic Associates Clinical Research Department has focused on bringing groundbreaking medication opportunities to patients in need. The clinical trials are designed to help evaluate medications & devices prior to FDA approval, as well as further evaluate post-approval medications. Bringing high-tech research to our community provides opportunities that allow our patients access to medications & devices that are on the cutting edge of science opening new avenues for those who are unable to obtain relief from other therapies. We have participated in many clinical trials for Multiple Sclerosis, Parkinson's disease, Huntington's disease, and compassionate access treatments for ALS.

Medical Staff

Deborah Lund, RN
Wendy Doroski, ANP-C
Kaitlyn Jaenicke
Olivia Kaczmarek

Enrolling Studies as of 08/19/2020

Study Name

Coordinator

Extension

Disease

Study Description

Argenx ADHERE ARGX-113-1802/1902
Deborah/Kaitlyn 2205/2246 CIDP A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (ADHERE)
ENLIGHTEN
RPC-1063-MS-001
Deborah/Kaitlyn 2205/2246 MS A Multicenter, Longitudinal, Open-Label, Single-arm study describing cognitive processing speed changes in relapsing multiple sclerosis subject treated with ozanimod (RPC-1063).
EVOLUTION MS200527_0080 Deborah/Kaitlyn 2205/2246 MS A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety.
GEMINI 2
EFC16034
Deborah/Kaitlyn 2205/2246 MS A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide (Aubagio®) in participants with relapsing forms of multiple sclerosis.
OCEAN 231MS201 Deborah/Kaitlyn 2205/2246 MS A multicenter, double-blind, placebo-controlled, parallel-group, dose ranging Phase 2 study to evaluate the efficacy and safety of oral BIIB061 as add-on therapy to interferon-beta 1 or Glatiramer Acetate therapies in relapsing MS.
ROPAD
Wendy/Olivia 2207/2206 Parkinson's Rostock International Parkinson’s Disease Study
Program: An International, Multicenter, Epidemiological Observational Study
All Parkinson’s patients are eligible for free genetic testing.
VERISMO BA39731 Deborah/Kaitlyn 2205/2246 MS An Observational study of Ocrelizumab-treated patients with multiple sclerosis to determine the incidence and mortality rates of breast cancer and all malignancies.

Locations this service is offered at:

Patchogue
77 Medford Avenue (Route 112)
Patchogue, NY 11772

Tel: 631-758-1910
Fax: 631-750-1014